Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Promising HAE Drug | Pharvaris's deucrictibant shows superior efficacy in resolving HAE attacks, positioning it as a potential best-in-class oral treatment for both acute and prophylactic use. |
Financial Fortitude | With $397 million in cash, Pharvaris has a two-year runway to advance clinical trials, despite higher-than-expected R&D expenses and operating losses. |
Market Opportunity | Explore Pharvaris's potential to capture a significant share of the $2+ billion HAE market, with peak sales estimates of $500M for acute and $1.5B for prophylactic use. |
Analyst Outlook | JMP Securities maintains a "Market Outperform" rating with a $50 price target, reflecting confidence in deucrictibant's potential and Pharvaris's strong market positioning. |
Metrics to compare | PHVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHVSPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.6x | −0.8x | −0.5x | |
PEG Ratio | 0.58 | −0.02 | 0.00 | |
Price/Book | 5.8x | 0.7x | 2.6x | |
Price / LTM Sales | - | 2.9x | 3.3x | |
Upside (Analyst Target) | 44.9% | 275.0% | 42.8% | |
Fair Value Upside | Unlock | 13.8% | 6.5% | Unlock |